With coronavirus cases around the world now at over 16
million, scientists have been working around the clock to develop a treatment.
Now, a new study suggests that an arthritis drug could be the
breakthrough we’ve all been waiting for.
Researchers from Imperial College London say that a drug
called tocilizumab could treat Covid-19 by halting the immune system ‘storm’
that the body produces in response to infection.
The drug is being tested on 450 coronavirus patients around the world.
- 1 Jesus hits double as rampant Man City go 15 points clear with Wolves win
- 2 Wolves' boss: Adama Traore uses baby oil to blaze past defenders
- 3 'Njoro' steadily following in the footsteps of big brother CJ Wangai
- 4 Pool: 512 pool teams aim for cash prize in Meru tournament
Dr Levi Garraway, Chief Medical Officer at Roche, which
makes the drug, said: “As more information about COVID-19 pneumonia becomes
available in these unprecedented times, it is more important than ever to work
together to fight this disease.
“Based on our current understanding, we believe that
combining an antiviral with an immune modulator could potentially be an
effective approach to treating patients with severe disease.”
Tocilizumab was originally developed as a treatment for
rheumatoid arthritis, and stops the immune system from over-responding and
attacking the body.
Speaking to the Daily
Mail, Dr Taryn Youngstein, who worked on the trial, said: “It’s very
clear that the major form of Covid that kills people is related to... the
body’s response to the virus – rather than the virus itself.
"We need to think about how we can suppress this
“We are very familiar with the drug. We know it’s very safe
and very well-tolerated. The question is whether it works in Covid-19.”
The trial results are expected this week.